TD Cowen lowered the firm’s price target on Surgery Partners (SGRY) to $28 from $32 and keeps a Buy rating on the shares. The firm updated its model following Q4 results which were generally inline with FY25 and guidance slightly below.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SGRY:
- Surgery Partners: Strong Growth and Strategic Positioning Drive Buy Rating
- Surgery Partners: Strong Financial Performance and Strategic Growth Drive Buy Rating
- Surgery Partners Delays Annual Report Filing
- Buy Rating for Surgery Partners: Strong Revenue Growth, Strategic Developments, and Market Opportunities
- Surgery Partners price target lowered to $35 from $40 at Benchmark